Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density

[1]  T. Sawada,et al.  Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. , 2000, International journal of molecular medicine.

[2]  R. Henriksson,et al.  p53 and vascular‐endothelial‐growth‐factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma , 2000, International journal of cancer.

[3]  P. Malfertheiner,et al.  Analysis of K‐ras gene mutations in rare pancreatic and ampullary tumours , 1998, European journal of gastroenterology & hepatology.

[4]  Keizo Sugimachi,et al.  Enhanced expression of thrombospondin‐1 and hypovascularity in human cholangiocarcinoma , 1998, Hepatology.

[5]  T. King,et al.  Molecular pathobiology of pancreatic adenocarcinoma. , 1998, Frontiers in bioscience : a journal and virtual library.

[6]  G. Klöppel,et al.  The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas , 1998, Virchows Archiv.

[7]  R. Hynes,et al.  Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo , 1998, Cell.

[8]  D. Berger,et al.  The Effect of Thrombospondin-1 and TGF-β1 on Pancreatic Cancer Cell Invasion , 1998 .

[9]  A. Yajima,et al.  Tumor angiogenesis, hepatocyte growth factor, and c‐Met expression in endometrial carcinoma , 1998 .

[10]  M. Janicek,et al.  Tumor angiogenesis as a prognostic factor in ovarian carcinoma , 1997, Cancer.

[11]  S. Leinster,et al.  Examining the technique of angiogenesis assessment in invasive breast cancer. , 1997, British Journal of Cancer.

[12]  K. Wakasa,et al.  Tumor angiogenesis as a major prognostic factor in stage I lung adenocarcinoma. , 1997, Anticancer research.

[13]  D. Berger,et al.  Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. , 1997, Surgery.

[14]  H. Friess,et al.  Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  S. Groshen,et al.  Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. , 1997, Journal of the National Cancer Institute.

[16]  N. Bertin,et al.  Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. , 1997, Cancer research.

[17]  S. Fox,et al.  Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. , 1996, European journal of cancer.

[18]  D. Roberts,et al.  Regulation of tumor growth and metastasis by thrombospondin‐1 , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  D. Parkinson,et al.  Clinical implications of tumor‐associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas , 1996, Cancer.

[20]  G. Tuszynski,et al.  Expression of Thrombospondin-1 in Cancer: A Role in Tumor Progression , 1996, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[21]  R. Cote,et al.  Immunohistochemical detection of thrombospondin-1 in formalin-fixed, paraffin-embedded tissue. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[22]  S. Leurgans,et al.  Tumor Angiogenesis as a Predictor of Recurrence and Survival in Patients with Node‐Negative Colon Cancer , 1995, Annals of surgery.

[23]  H. Friess,et al.  Induction and expression of amphiregulin in human pancreatic cancer. , 1994, Cancer research.

[24]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[25]  O. Volpert,et al.  Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity , 1993, The Journal of cell biology.

[26]  V. Dixit,et al.  Motility of human carcinoma cells in response to thrombospondin: relationship to metastatic potential and thrombospondin structural domains. , 1993, Cancer research.

[27]  D. Capuzzi,et al.  Thrombospondin Levels in Patients with Malignancy , 1992, Thrombosis and Haemostasis.

[28]  M. L. Le Beau,et al.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[29]  L. Liotta,et al.  Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor , 1990, The Journal of cell biology.

[30]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[31]  W. Miller,et al.  Thrombospondin in malignant and non-malignant breast tissue. , 1989, European journal of cancer & clinical oncology.

[32]  G. Tuszynski,et al.  Thrombospondin, a potentiator of tumor cell metastasis. , 1987, Cancer research.

[33]  A. Balmain,et al.  Cloning and characterisation of the abundant cytoplasmic 7S RNA from mouse cells. , 1982, Nucleic acids research.

[34]  C. Angeletti,et al.  Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  T. Kurosaki,et al.  Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma. , 1998, Cancer detection and prevention.

[36]  R. Hynes,et al.  Thrombospondin-1 is a major activator of TGF-beta1 in vivo. , 1998, Cell.

[37]  D. Berger,et al.  The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion. , 1998, The Journal of surgical research.